Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 4/20 | 0.55 |
| ▸ | MAX | P61244 | 3/20 | 0.55 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | ACP1 | P24666 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 5/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17927366 | 0.94 | MYC (0.57) | MYCMAXCISD1KDRMAPK1 | |
| SCHEMBL17927363 | 0.94 | MYC (0.57) | MYCMAXCISD1KDRMAPK1 | |
| SCHEMBL17927407 | 0.89 | MYC (0.57) | MYCMAXKDRPTPN1ACP1 | |
| SCHEMBL17927408 | 0.89 | MYC (0.57) | MYCMAXKDRPTPN1ACP1 | |
| SCHEMBL17927388 | 0.81 | MYC (0.58) | MYCMAXCISD1MAPK1MAOA | |
| SCHEMBL17927386 | 0.81 | MYC (0.58) | MYCMAXCISD1MAPK1MAOA | |
| SCHEMBL17927375 | 0.81 | MYC (0.60) | MYCMAXKDRMAPK1 | |
| SCHEMBL17927373 | 0.81 | MYC (0.60) | MYCMAXKDRMAPK1 | |
| SCHEMBL17927303 | 0.81 | MYC (0.52) | MYCMAXCISD1MAPK1MAOA | |
| SCHEMBL17927304 | 0.81 | MYC (0.52) | MYCMAXCISD1MAPK1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| WO-2016115360-A1 | C-MYC LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2016-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | XIAP, CUL4A, CUL1 | MYC 226/4885MAX 1243/4885CISD1 1791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.